BIOA (Bioage Labs) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Days Payable?

Bioage Labs's average Accounts Payable for the three months ended in Dec. 2024 was $2.05 Mil. Bioage Labs's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Bioage Labs's Days Payable or its related term are showing as below:

BIOA's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 85.92
* Ranked among companies with meaningful Days Payable only.

Bioage Labs's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Bioage Labs Days Payable Historical Data

The historical data trend for Bioage Labs's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Days Payable Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Days Payable

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Bioage Labs's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Days Payable distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Days Payable falls into.

Save Embed

;

Save Embed

;

Bioage Labs Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Bioage Labs's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (1.866	+	1.996)	/	2 )	/	0	*	365
=	1.931					/	0	*	365
=	N/A

Bioage Labs's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (2.098	+	1.996)	/	2 )	/	0	*	365 / 4
=	2.047					/	0	*	365 / 4
=	N/A

Bioage Labs Days Payable Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.